UA109927C2 - Конденсированные производные аминодигидротиазина, полезные как ингибиторы васе - Google Patents

Конденсированные производные аминодигидротиазина, полезные как ингибиторы васе

Info

Publication number
UA109927C2
UA109927C2 UAA201310161A UAA201310161A UA109927C2 UA 109927 C2 UA109927 C2 UA 109927C2 UA A201310161 A UAA201310161 A UA A201310161A UA A201310161 A UAA201310161 A UA A201310161A UA 109927 C2 UA109927 C2 UA 109927C2
Authority
UA
Ukraine
Prior art keywords
derivatives useful
fused aminodihydrothiazine
bace inhibitors
inhibitory effect
aminodihydrothiazine derivatives
Prior art date
Application number
UAA201310161A
Other languages
English (en)
Ukrainian (uk)
Inventor
Адріан Холл
Крістофер Нейл Фартінг
Пінейро Хосе Луіс Кастро
Original Assignee
Ейсей Р Енд Д Менеджмент Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43769479&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA109927(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ейсей Р Енд Д Менеджмент Ко., Лтд. filed Critical Ейсей Р Енд Д Менеджмент Ко., Лтд.
Publication of UA109927C2 publication Critical patent/UA109927C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Это изобретение касается конденсированного производного аминдигидротиазина формулы (I): EMBED ISISServer , (I) где X - водород или фтор; А - СН или N; Υ - метил, этил, монофторметил, дифторметил, трифторметил, дифторетил, метокси, этокси, метоксиметил или -C=N; и его фармацевтически приемлемых солей; причем это соединение имеет ингибирующее действие на выработку Αβ или на ВАСЕ1 и служит средством для профилактики или лечения нейродегенеративной болезни, вызванной Αβ, типичным проявлением которой является деменция типа Альцгеймера.
UAA201310161A 2011-01-21 2012-01-20 Конденсированные производные аминодигидротиазина, полезные как ингибиторы васе UA109927C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1101140.0A GB201101140D0 (en) 2011-01-21 2011-01-21 Fused aminodihydrothiazine derivatives
PCT/EP2012/050833 WO2012098213A1 (en) 2011-01-21 2012-01-20 Fused aminodihydrothiazine derivatives useful as bace inhibitors

Publications (1)

Publication Number Publication Date
UA109927C2 true UA109927C2 (ru) 2015-10-26

Family

ID=43769479

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201310161A UA109927C2 (ru) 2011-01-21 2012-01-20 Конденсированные производные аминодигидротиазина, полезные как ингибиторы васе

Country Status (21)

Country Link
US (3) US8338407B2 (ru)
EP (1) EP2665732B1 (ru)
JP (1) JP5947815B2 (ru)
KR (1) KR101906466B1 (ru)
CN (1) CN103328486B (ru)
AR (1) AR084903A1 (ru)
AU (1) AU2012208526B2 (ru)
BR (1) BR112013018602A2 (ru)
CA (1) CA2828738A1 (ru)
CL (1) CL2013002083A1 (ru)
ES (1) ES2575914T3 (ru)
GB (1) GB201101140D0 (ru)
IL (1) IL226596A (ru)
MX (1) MX2013007917A (ru)
PE (1) PE20141182A1 (ru)
RU (1) RU2593756C2 (ru)
SG (1) SG190908A1 (ru)
TW (1) TW201309710A (ru)
UA (1) UA109927C2 (ru)
WO (1) WO2012098213A1 (ru)
ZA (1) ZA201303801B (ru)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1942105B8 (en) 2005-10-25 2014-08-13 Shionogi&Co., Ltd. Aminodihydrothiazine derivative
KR20100017255A (ko) 2007-04-24 2010-02-16 시오노기 앤드 컴파니, 리미티드 환식기로 치환된 아미노다이하이드로싸이아진 유도체
US8653067B2 (en) 2007-04-24 2014-02-18 Shionogi & Co., Ltd. Pharmaceutical composition for treating Alzheimer's disease
KR101564634B1 (ko) 2008-01-18 2015-10-30 에자이 알앤드디 매니지먼트 가부시키가이샤 축합 아미노디하이드로 티아진 유도체
US8637504B2 (en) 2008-06-13 2014-01-28 Shionogi & Co., Ltd. Sulfur-containing heterocyclic derivative having beta secretase inhibitory activity
EP2360155A4 (en) 2008-10-22 2012-06-20 Shionogi & Co 2-AMINOPYRIDIN-4-ON AND 2-AMINOPYRIDINE DERIVATIVE WITH BACE1-HEMDERING EFFECT
GB0912777D0 (en) 2009-07-22 2009-08-26 Eisai London Res Lab Ltd Fused aminodihydropyrimidone derivatives
GB0912778D0 (en) 2009-07-22 2009-08-26 Eisai London Res Lab Ltd Fused aminodihydro-oxazine derivatives
WO2011044185A2 (en) 2009-10-08 2011-04-14 Schering Corporation Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use
EP2485591B1 (en) 2009-10-08 2016-03-23 Merck Sharp & Dohme Corp. Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
RU2012129168A (ru) 2009-12-11 2014-01-20 Сионоги Энд Ко. Лтд. Производные оксазина
JP5766198B2 (ja) 2010-10-29 2015-08-19 塩野義製薬株式会社 縮合アミノジヒドロピリミジン誘導体
CA2816285A1 (en) 2010-10-29 2012-05-03 Shionogi & Co., Ltd. Naphthyridine derivative
GB201100181D0 (en) 2011-01-06 2011-02-23 Eisai Ltd Fused aminodihydrothiazine derivatives
SG10201601516QA (en) 2011-01-21 2016-03-30 Eisai R&D Man Co Ltd Methods and compounds useful in the synthesis of fused aminodihydrothiazine derivatives
GB201101140D0 (en) 2011-01-21 2011-03-09 Eisai Ltd Fused aminodihydrothiazine derivatives
GB201101139D0 (en) 2011-01-21 2011-03-09 Eisai Ltd Fused aminodihydrothiazine derivatives
CN103608345A (zh) 2011-04-26 2014-02-26 盐野义制药株式会社 噁嗪衍生物和含有该噁嗪衍生物的bace1抑制剂
EP2763676B1 (en) * 2011-10-03 2019-12-25 The University of Utah Research Foundation Application of 5-ht6 receptor antagonists for the alleviation of cognitive deficits of down syndrome
WO2014015125A1 (en) 2012-07-19 2014-01-23 Eisai R&D Management Co., Ltd. Fused aminodihydrothiazine derivative salts and uses thereof
GB201212816D0 (en) * 2012-07-19 2012-09-05 Eisai Ltd Novel compounds
EP2893042B1 (en) * 2012-09-05 2018-02-14 Emory University Diagnostic testing in dementia and methods related thereto
WO2014065434A1 (en) 2012-10-24 2014-05-01 Shionogi & Co., Ltd. Dihydrooxazine or oxazepine derivatives having bace1 inhibitory activity
TWI593692B (zh) * 2013-03-12 2017-08-01 美國禮來大藥廠 四氫吡咯并噻嗪化合物
JO3318B1 (ar) 2013-06-18 2019-03-13 Lilly Co Eli مثبطات bace
TWI599358B (zh) * 2014-09-16 2017-09-21 美國禮來大藥廠 組合療法
AR103680A1 (es) * 2015-02-23 2017-05-24 Lilly Co Eli Inhibidores selectivos de bace1
EP3271356B1 (en) * 2015-03-19 2019-10-16 Eli Lilly and Company Selective bace1 inhibitors
AR104241A1 (es) * 2015-04-29 2017-07-05 Lilly Co Eli Derivados de tetrahidrofuro tiazina como inhibidores de bace1 selectivos
TW201740954A (zh) * 2016-03-16 2017-12-01 美國禮來大藥廠 組合療法
KR20170108203A (ko) * 2016-03-16 2017-09-27 주식회사 피플바이오 응집형-형성 폴리펩타이드의 응집형을 검출하는 방법
TWI675034B (zh) * 2016-05-20 2019-10-21 美商美國禮來大藥廠 四氫呋喃并<img align="absmiddle" height="18px" width="27px" file="d10999.TIF" alt="其他非圖式 ed10999.png" img-content="tif" orientation="portrait" inline="yes" giffile="ed10999.png"></img>化合物及其作為選擇性ＢＡＣＥ１抑制劑之用途
WO2018034977A1 (en) * 2016-08-18 2018-02-22 Eli Lilly And Company Combination therapy of bace-1 inhibitor and anti-n3pglu abeta antibody
AR110470A1 (es) * 2016-10-21 2019-04-03 Lilly Co Eli Terapia de combinación para tratar la enfermedad de alzheimer
EP3555085B1 (en) 2016-12-15 2020-12-02 Amgen Inc. Cyclopropyl fused thiazine derivatives as beta-secretase inhibitors and methods of use
EP3555106B1 (en) * 2016-12-15 2022-03-09 Amgen Inc. Bicyclic thiazine and oxazine derivatives as beta-secretase inhibitors and methods of use
WO2018112081A1 (en) 2016-12-15 2018-06-21 Amgen Inc. Oxazine derivatives as beta-secretase inhibitors and methods of use
CA3047288A1 (en) 2016-12-15 2018-06-21 Amgen Inc. Thiazine derivatives as beta-secretase inhibitors and methods of use
US11021493B2 (en) 2016-12-15 2021-06-01 Amgen Inc. 1,4-thiazine dioxide and 1,2,4-thiadiazine dioxide derivatives as beta-secretase inhibitors and methods of use
CN116143621A (zh) * 2022-12-14 2023-05-23 湖南农业大学 一种硼盐催化激活酰胺用于制备苯甲酸酯类化合物的方法

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3227713A (en) 1966-01-04 Azine derivatives
US3235551A (en) 1966-02-15 Novel derivatives of
RU2128175C1 (ru) * 1994-08-09 1999-03-27 Эйсай Ко., Лтд. Конденсированный пиридазин или его фармакологически приемлемая соль, средство, проявляющее ингибирующую активность в отношении циклической гмф- фосфодиэстеразы
JPH0967355A (ja) 1995-08-31 1997-03-11 Tokyo Tanabe Co Ltd チアジン誘導体、チアゾール誘導体及びそれらの製造方法
US6642237B1 (en) 1999-11-24 2003-11-04 Merck & Co., Inc. Gamma-hydroxy-2-(fluoroalkylaminocarbonyl)-1-piperazinepentanamides and uses thereof
CN1251671C (zh) 2000-05-19 2006-04-19 武田药品工业株式会社 β分泌酶抑制剂
US6562783B2 (en) 2001-05-30 2003-05-13 Neurologic, Inc. Phosphinylmethyl and phosphorylmethyl succinic and glutauric acid analogs as β-secretase inhibitors
NZ560368A (en) 2002-05-03 2008-11-28 Israel Inst Biolog Res Methods and compostions for treatment of central and peripheral nervous system disorders and novel compounds useful therefor
AU2003254844A1 (en) 2002-08-09 2004-02-25 Takeda Chemical Industries, Ltd. Substituted amino compounds and use thereof
AU2003285012A1 (en) 2002-10-24 2004-05-13 Sepracor, Inc. Compositions comprising zopiclone derivatives and methods of making and using the same
JP2004149429A (ja) 2002-10-29 2004-05-27 Takeda Chem Ind Ltd インドール化合物およびその用途
CA2505098A1 (en) 2002-11-12 2004-05-27 Merck & Co., Inc. Phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer's disease
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7700603B2 (en) 2003-12-15 2010-04-20 Schering Corporation Heterocyclic aspartyl protease inhibitors
MXPA06006730A (es) 2003-12-15 2006-08-31 Schering Corp Inhibidores de aspartil proteasa heterociclicos.
EP1732906A4 (en) 2004-03-30 2007-11-21 Merck & Co Inc 2-AMINOTHIAZOLE COMPOUNDS USEFUL AS ASPARTYLE-PROTEASE INHIBITORS
PE20060664A1 (es) 2004-09-15 2006-08-04 Novartis Ag Amidas biciclicas como inhibidores de cinasa
WO2006041405A1 (en) 2004-10-15 2006-04-20 Astrazeneca Ab Substituted amino-pyrimidones and uses thereof
EP1802587A4 (en) 2004-10-15 2010-02-17 Astrazeneca Ab SUBSTITUTED AMINO BINDINGS AND THEIR APPLICATIONS
WO2006078577A1 (en) 2005-01-19 2006-07-27 Merck & Co., Inc. Tertiary carbinamines having substituted heterocycles, which are active as inhibitors of beta-secretase, for the treatment of alzheimer's disease
AR054617A1 (es) 2005-06-14 2007-07-04 Schering Corp Derivados de pirrol[3, 4 - d]pirimidina como inhibidores de aspartil proteasas y composiciones farmacéuticas que los comprenden
WO2007011810A1 (en) 2005-07-18 2007-01-25 Merck & Co., Inc. Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
EP1942105B8 (en) 2005-10-25 2014-08-13 Shionogi&Co., Ltd. Aminodihydrothiazine derivative
JP2009532464A (ja) 2006-04-05 2009-09-10 アストラゼネカ・アクチエボラーグ ２−アミノピリミジン−４−オン及びＡβ−関連の病理を治療又は予防するためのその使用
US8049006B2 (en) 2006-05-31 2011-11-01 Daiichi Sankyo Company, Limited 7-membered ring compound and method of production and pharmaceutical application thereof
WO2007146225A2 (en) 2006-06-12 2007-12-21 Schering Corporation Heterocyclic aspartyl protease inhibitors
KR20090087487A (ko) 2006-12-12 2009-08-17 쉐링 코포레이션 아스파르틸 프로테아제 억제제
US8653067B2 (en) 2007-04-24 2014-02-18 Shionogi & Co., Ltd. Pharmaceutical composition for treating Alzheimer's disease
KR20100017255A (ko) 2007-04-24 2010-02-16 시오노기 앤드 컴파니, 리미티드 환식기로 치환된 아미노다이하이드로싸이아진 유도체
PE20091236A1 (es) 2007-11-22 2009-09-16 Astrazeneca Ab Derivados de pirimidina como immunomoduladores de tlr7
KR101564634B1 (ko) 2008-01-18 2015-10-30 에자이 알앤드디 매니지먼트 가부시키가이샤 축합 아미노디하이드로 티아진 유도체
TW201004957A (en) 2008-04-22 2010-02-01 Schering Corp Phenyl-substituted 2-imino-3-methyl pyrrolo pyrimidinone compounds as bace-1 inhibitors, compositions, and their use
TWI431004B (zh) 2008-05-02 2014-03-21 Lilly Co Eli Ｂａｃｅ抑制劑
US8637504B2 (en) 2008-06-13 2014-01-28 Shionogi & Co., Ltd. Sulfur-containing heterocyclic derivative having beta secretase inhibitory activity
WO2010013302A1 (ja) 2008-07-28 2010-02-04 エーザイ・アール・アンド・ディー・マネジメント株式会社 スピロアミノジヒドロチアジン誘導体
EP2318416B1 (en) 2008-07-28 2013-09-04 Eisai R&D Management Co., Ltd. Spiroaminodihydrothiazine derivatives
US8450308B2 (en) 2008-08-19 2013-05-28 Vitae Pharmaceuticals, Inc. Inhibitors of beta-secretase
TW201016708A (en) * 2008-09-30 2010-05-01 Eisai R&D Man Co Ltd Novel fused aminodihydrothiazine derivative
PT2406240E (pt) 2009-03-13 2016-02-24 Boehringer Ingelheim Int Inibidores de beta-secretase
AR077277A1 (es) * 2009-07-09 2011-08-17 Lilly Co Eli Compuestos de biciclo (1,3)tiazin-2-amina formulacion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para el tratamiento de la enfermedad de alzheimer
GB0912777D0 (en) 2009-07-22 2009-08-26 Eisai London Res Lab Ltd Fused aminodihydropyrimidone derivatives
GB0912778D0 (en) 2009-07-22 2009-08-26 Eisai London Res Lab Ltd Fused aminodihydro-oxazine derivatives
CA2803009A1 (en) 2010-07-01 2012-01-05 Amgen Inc. Heterocyclic compounds and their use as inhibitors of pi3k activity
GB201100181D0 (en) 2011-01-06 2011-02-23 Eisai Ltd Fused aminodihydrothiazine derivatives
GB201101139D0 (en) 2011-01-21 2011-03-09 Eisai Ltd Fused aminodihydrothiazine derivatives
GB201101140D0 (en) 2011-01-21 2011-03-09 Eisai Ltd Fused aminodihydrothiazine derivatives
SG10201601516QA (en) 2011-01-21 2016-03-30 Eisai R&D Man Co Ltd Methods and compounds useful in the synthesis of fused aminodihydrothiazine derivatives

Also Published As

Publication number Publication date
ZA201303801B (en) 2014-07-30
CN103328486B (zh) 2016-08-17
CN103328486A (zh) 2013-09-25
JP5947815B2 (ja) 2016-07-06
NZ611365A (en) 2015-04-24
EP2665732B1 (en) 2016-03-30
GB201101140D0 (en) 2011-03-09
KR20140002724A (ko) 2014-01-08
US8592408B2 (en) 2013-11-26
WO2012098213A1 (en) 2012-07-26
US8940734B2 (en) 2015-01-27
PE20141182A1 (es) 2014-09-14
KR101906466B1 (ko) 2018-10-10
JP2014502987A (ja) 2014-02-06
AU2012208526B2 (en) 2015-09-24
AR084903A1 (es) 2013-07-10
AU2012208526A1 (en) 2013-05-02
TW201309710A (zh) 2013-03-01
US8338407B2 (en) 2012-12-25
SG190908A1 (en) 2013-07-31
EP2665732A1 (en) 2013-11-27
US20120190672A1 (en) 2012-07-26
ES2575914T3 (es) 2016-07-04
US20130203740A1 (en) 2013-08-08
US20140142091A1 (en) 2014-05-22
CL2013002083A1 (es) 2013-12-06
BR112013018602A2 (pt) 2020-09-01
CA2828738A1 (en) 2012-07-26
RU2013138717A (ru) 2015-02-27
MX2013007917A (es) 2013-08-29
IL226596A (en) 2016-04-21
RU2593756C2 (ru) 2016-08-10

Similar Documents

Publication Publication Date Title
UA109927C2 (ru) Конденсированные производные аминодигидротиазина, полезные как ингибиторы васе
MX2013008255A (es) Derivados de aminodihidrotiazina fusionada.
MD4582B1 (ru) Производные 1-фенил-1H-бензимидазола в качестве ингибиторов протеинкиназы
AU2012313888A8 (en) 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH
MA38050B1 (fr) Inhibiteurs de gdf-8
MX2013013041A (es) Nuevos compuestos y composiciones para la inhibicion de nampt.
MD20180040A2 (ru) Ингибиторы вируса гепатита С
IN2014MN02106A (ru)
GEP201606532B (en) Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1
WO2013038429A3 (en) Novel sglt inhibitors
IN2014MN01521A (ru)
EP2590649A4 (en) PROCESS FOR SYNTHESIS OF SUBSTITUTED MORPHINANES
WO2012172566A3 (en) Novel sglt inhibitors
MY150774A (en) Isoquinoline derivative
EA201290165A1 (ru) Способ получения производного фенилаланина
IN2014MN00850A (ru)
GB2482826A (en) Synthesis of morphine and related derivatives
MX337997B (es) Nuevo procedimiento de sintesis de la ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable.
MX359399B (es) Inhibidores de 17alfa-hidroxilasa/c17-20-liasa.
SG195071A1 (en) Novel process for the synthesis of 7-chloro-4-(piperazin-1-yl)-quinoline
GEP20135737B (en) New method for synthesis of ivabradine and acid-additive salts thereof
IN2013MU04056A (ru)
GEP20156269B (en) New secondary 8-hydroxyquinoline-7- carboxamide derivatives
FR2970000B1 (fr) Nouveau procede de synthese de l&#39;agomelatine
IN2015DN00659A (ru)